Evidence map›Paper›PMID 39606606›Full record

ArticlePostepy dermatologii i alergologii2024

Sensitization to α-gal and omega-5-gliadin in patients with chronic urticaria: clinical implications and need for targeted testing.

Vesna Vukičević Lazarević, Marina Božan, Ivica Lokner, Alda Ranogajec

Abstract read
In one paragraph

Article in Postepy dermatologii i alergologii, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vesna Vukičević LazarevićSpecial Hospital for Pulmonary Diseases, Zagreb, Croatia.
Marina BožanSpecial Hospital for Pulmonary Diseases, Zagreb, Croatia.
Ivica LoknerSpecial Hospital for Pulmonary Diseases, Zagreb, Croatia.
Alda RanogajecSpecial Hospital for Pulmonary Diseases, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic urticaria (CU) is defined as the presence of recurring hives and/or angioedema lasting more than 6 weeks. The precise impact of food allergies, particularly to galactose-α-1,3-galactose (α-gal) and omega-5-gliadin (O5G), on the development of CU is not well established. Aim: The study examines the frequency of sensitisation to these allergens and their clinical significance in individuals with CU. Material and methods: We recruited 100 adults newly diagnosed with CU to evaluate the presence of specific immunoglobulin E antibodies and allergies to α-gal and O5G. The patients were categorised into three groups based on their specific IgE levels: those sensitised to α-gal, those sensitised to O5G, and those not sensitised to either. Demographic, clinical, and laboratory variables were compared across the groups. Results: The findings indicated that 5% of the cohort was sensitised to α-gal, and 4% showed sensitivity to O5G, while only 4% of patients had a convincing history of food allergy (two to red meat and two to wheat). The sensitised groups exhibited the greatest levels of total IgE, and had a higher proportion of males. The α-gal group showed higher levels of specific IgE to Ascaris lumbricoides than the group without sensitisation. The groups had similar features in all other assessed aspects. Conclusions: Our CU cohort's sensitivity and convincing food allergy to α-gal and O5G were comparatively modest. While routine screening may not be essential, focused testing of individuals with severe or uncommon symptoms might enhance the accuracy of diagnosis and treatment.

Indexed as

allergen sensitisationchronic urticariafood allergyomega-5 gliadinα-gal

Identifiers

PMID39606606
PMCPMC11589628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.